Allylescaline

Uncontrolled hypertension, Heart failure, Recent myocardial infarction, Severe arrhythmias

Mescaline-class phenethylamine psychedelics produce transient increases in blood pressure and heart rate. A systematic review of mescaline (Shaw et al. 2026) identified hypertension as a commonly reported adverse effect. Individuals with severe cardiovascular disease face elevated risk from these hemodynamic changes.

Current lithium carbonate therapy

Case reports in the broader psychedelic literature document seizures when lithium is combined with serotonergic psychedelics. No allylescaline-specific data exists. The mechanism is poorly understood but the combination is considered absolutely contraindicated in harm reduction literature.

Epilepsy, History of seizures, Conditions lowering seizure threshold

Seizures have been reported in 2C-series phenethylamine intoxications (Dean et al. 2013). While allylescaline's 3,5-dimethoxy substitution pattern differs from the 2,5-dimethoxy 2C series, the general class concern applies. Risk likely dose-dependent and primarily relevant at high doses.

Schizophrenia, Schizoaffective disorder, Bipolar disorder with psychotic features, Family history of psychotic disorders

Serotonergic psychedelics acting at 5-HT2A receptors carry established class-level risk of precipitating psychotic episodes in vulnerable individuals. No allylescaline-specific data exists, but the risk is well-documented across the phenethylamine and tryptamine psychedelic classes.

Pregnancy, Breastfeeding

No reproductive safety data exists for allylescaline or any scaline-class compound. Teratogenic potential is unknown. Given the complete absence of safety data and the compound's psychoactive properties, pregnancy is an absolute contraindication on precautionary grounds.

Irreversible MAOIs (phenelzine, tranylcypromine), Reversible MAOIs (moclobemide), Ayahuasca/harmine/harmaline

Monoamine oxidase is a primary metabolic enzyme for phenethylamines. Concurrent MAOI use can produce life-threatening increases in phenethylamine bioavailability, hypertensive crisis, and serotonin toxicity. This is a class-level contraindication with no allylescaline-specific interaction data.